Login
Manage Portfolio
Post a StockTalk
Write an Instablog
Get Daily Email Alert
Seeking Alpha
Home
The Macro View
Stocks & Sectors
Global Markets
ETFs
Investing Ideas
Breaking News
Transcripts
Business Intelligence
BioCryst Pharmaceuticals Inc. (BCRX)
(
)
Quotes
Dashboard
Chart
Historical Prices
Options
Analysis
Articles
Instablogs
StockTalks
Sentiment
Comments
News & PR
Market Currents
Buzz
Twitter: BCRX
Coverage
Top Authors
Cramer
Top Analysts
Business Intelligence
Transcripts
Events
Key Developments
Earnings
History & Projected
Consensus
Peer Earnings
Filings
SEC Filings
Annual Report
Ownership
Major Holders
Insider Trades
Insider Sentiment
Index Membership
Short Interest
Financials
Income Statement
Balance Sheet
Cash Flow
Company
Wikipedia Profile
Officers & Directors
Executive Comp
Analysis - Latest Articles
by
most recent
|
most commented
BioCryst: H1N1 Antiviral Partner Gets Fast Tracked for Japanese Review
Dec 9
•
Michael Murphy
•
9 Comments
BioCryst's Korean Partner Receives Emergency Use Authorization
Dec 9
•
Michael Murphy
•
17 Comments
Short Blood Supply Means Long Outlook for Cerus
Nov 15
•
Michael Shulman
•
2 Comments
Thursday Options Recap
Nov 12
•
Frederic Ruffy
•
1 Comment
Why Has Cel-Sci Quietly Amended Some Previously Filed Paperwork?
Nov 12
•
M. E. Garza
•
14 Comments
Wall Street Breakfast: Must-Know News
Oct 29
•
SA Editor Eli Hoffmann
•
15 Comments
BioMed Momentum Index: A Pause that Refreshes or More Pain to Come?
Oct 29
•
Mike Havrilla
•
1 Comment
Tuesday Options Recap
Oct 27
•
Frederic Ruffy
•
Comment!
Equities Update: Oil Drops, Stocks Too
Oct 26
•
Midnight Trader
•
4 Comments
Monday Options Recap
Oct 26
•
Frederic Ruffy
•
Comment!
Wall Street Breakfast: Must-Know News
Oct 26
•
SA Editor Eli Hoffmann
•
14 Comments
Friday's Options Recap
Oct 16
•
Frederic Ruffy
•
3 Comments
Movers and Shakers Include Flu Stocks Sinovac and BioCryst Pharma
Oct 14
•
M. E. Garza
•
4 Comments
Swine Flu Stocks: Where Are They Now?
Oct 2
•
Everyday Finance
•
11 Comments
Surviving Wednesday's Wild Ride in Healthcare and Biotech
Oct 1
•
M. E. Garza
•
1 Comment
Onyx Pharmaceuticals: Nexavar Promising for Metastatic Breast Cancer
Sep 23
•
Prohost Biotech
•
1 Comment
Options Trader Monday Outlook: Microbe Mania
Sep 21
•
Philip Davis
•
9 Comments
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
Sep 20
•
Justin M. Hall
•
3 Comments
Closing Update: Dow's 0.6% Advance Leads the Way
Sep 15
•
Midnight Trader
•
5 Comments
BioCryst Jumps on Flu Drug Deal
Sep 15
•
optionMONSTER
•
Comment!
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up
Sep 11
•
Justin M. Hall
•
23 Comments
Megatrend Companies Summary
Sep 10
•
Bryan Gomez
•
12 Comments
Friday Options Recap
Sep 4
•
Frederic Ruffy
•
2 Comments
A Guide to Investing in the Next Decade
Aug 27
•
Bryan Gomez
•
2 Comments
Increased Interest in Cel-Sci After Latest SEC Filing
Aug 26
•
M. E. Garza
•
12 Comments
Closing Update for Tuesday, August 25: Dow Makes It Six Straight Gains
Aug 25
•
Midnight Trader
•
9 Comments
Stocks with 10x Gain Since March: Room to Run?
Aug 25
•
Dr. Kris
•
4 Comments
Wall Street Breakfast: Must-Know News
Jul 30
•
SA Editor Rachael Granby
•
16 Comments
Swine Flu Stocks - Just Wait Until Fall
Jul 29
•
Everyday Finance
•
29 Comments
Swine Flu Vaccines Will Have to Wait
Jul 14
•
David White
•
4 Comments
Big Lineup of Healthcare Stocks Crack the Russell 3000 Index
Jul 1
•
M. E. Garza
•
Comment!
Companies Involved in the Treatment of Swine Flu
Jun 17
•
Kaushik Paul
•
11 Comments
A Biotech Triple Play: Dendreon, BioCryst and Arena
May 25
•
Michael Murphy
•
28 Comments
How the U.S. Profits From Swine Flu
May 19
•
Jesse Veverka
•
2 Comments
Swine Flu: A Follow-Up on 'Trading the Hype'
May 4
•
Mike Stathis
•
Comment!
Swine Flu: Trade Smartly, Beware the Hype
Apr 30
•
Mike Stathis
•
23 Comments
Swine Flu Stock Watchlist
Apr 30
•
Babak
•
5 Comments
5 Potential Pandemic Shorts
Apr 29
•
Michael Shulman
•
4 Comments
Tuesday's Options Recap
Apr 28
•
Frederic Ruffy
•
Comment!
The Swine Flu Effect
Apr 28
•
Carol Flake Chapman
•
25 Comments
Beneficiaries and Losers from the Swine Flu Scare
Apr 28
•
Matthew D. McCall
•
4 Comments
1
2
Next Page